Assessment of the management of carcinomatous meningitis from breast cancer globally: a study by the Breast International Group Brain Metastasis Task Force
Standard
Assessment of the management of carcinomatous meningitis from breast cancer globally: a study by the Breast International Group Brain Metastasis Task Force. / Razis, E; Escudero, M J; Palmieri, C; Mueller, V; Bartsch, R; Rossi, G; Gampenrieder, S P; Kolberg, H C; Zdenkowski, N; Pavic, M; Connolly, R M; Rosset, L; Arcuri, J; Tesch, H; Vallejos, C; Retamales, J; Musolino, A; Del Mastro, L; Christodoulou, C; Aebi, S; Paluch-Shimon, S; Gupta, S; Ohno, S; Macpherson, I; Ekholm, M; Zaman, K; Vidal, M; Chakiba, C; Fumagalli, D; Thulin, A; Witzel, I; Kotecki, N; Gil-Gil, M; Linderholm, B.
in: ESMO OPEN, Jahrgang 7, Nr. 3, 100483, 06.2022.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Assessment of the management of carcinomatous meningitis from breast cancer globally: a study by the Breast International Group Brain Metastasis Task Force
AU - Razis, E
AU - Escudero, M J
AU - Palmieri, C
AU - Mueller, V
AU - Bartsch, R
AU - Rossi, G
AU - Gampenrieder, S P
AU - Kolberg, H C
AU - Zdenkowski, N
AU - Pavic, M
AU - Connolly, R M
AU - Rosset, L
AU - Arcuri, J
AU - Tesch, H
AU - Vallejos, C
AU - Retamales, J
AU - Musolino, A
AU - Del Mastro, L
AU - Christodoulou, C
AU - Aebi, S
AU - Paluch-Shimon, S
AU - Gupta, S
AU - Ohno, S
AU - Macpherson, I
AU - Ekholm, M
AU - Zaman, K
AU - Vidal, M
AU - Chakiba, C
AU - Fumagalli, D
AU - Thulin, A
AU - Witzel, I
AU - Kotecki, N
AU - Gil-Gil, M
AU - Linderholm, B
N1 - Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.
PY - 2022/6
Y1 - 2022/6
N2 - BACKGROUND: Carcinomatous meningitis (CM) is a severe complication of breast cancer. The Breast International Group (BIG) carried out a survey to describe the approach to CM internationally.PATIENTS AND METHODS: A questionnaire on the management of CM was developed by the Brain Metastases Task Force of BIG and distributed to its groups, requesting one answer per group site.RESULTS: A total of 241 sites responded, 119 from Europe, 9 from North America, 39 from Central/South America, 58 from Asia, and 16 in Australia/New Zealand, with 24.5% being general hospitals with oncology units, 44.4% university hospitals, 22.4% oncology centers, and 8.7% private hospitals. About 56.0% of sites reported seeing <5 cases annually with 60.6% reporting no increase in the number of cases of CM recently. Nearly 63.1% of sites investigate for CM when a patient has symptoms or radiological evidence, while 33.2% investigate only for symptoms. For diagnosis, 71.8% of sites required a positive cerebrospinal fluid cytology, while magnetic resonance imaging findings were sufficient in 23.7% of sites. Roughly 97.1% of sites treat CM and 51.9% also refer patients to palliative care. Intrathecal therapy is used in 41.9% of sites, mainly with methotrexate (74.3%). As many as 20 centers have a national registry for patients with breast cancer with central nervous system metastases and of those 5 have one for CM. Most (90.9%) centers would be interested in participating in a registry as well as in studies for CM, the latter preferably (62.1%) breast cancer subtype specific.CONCLUSIONS: This is the first study to map out the approach to CM from breast cancer globally. Although guidelines with level 1 evidence are lacking, there is a high degree of homogeneity in the approach to CM globally and great interest for conducting studies in this area.
AB - BACKGROUND: Carcinomatous meningitis (CM) is a severe complication of breast cancer. The Breast International Group (BIG) carried out a survey to describe the approach to CM internationally.PATIENTS AND METHODS: A questionnaire on the management of CM was developed by the Brain Metastases Task Force of BIG and distributed to its groups, requesting one answer per group site.RESULTS: A total of 241 sites responded, 119 from Europe, 9 from North America, 39 from Central/South America, 58 from Asia, and 16 in Australia/New Zealand, with 24.5% being general hospitals with oncology units, 44.4% university hospitals, 22.4% oncology centers, and 8.7% private hospitals. About 56.0% of sites reported seeing <5 cases annually with 60.6% reporting no increase in the number of cases of CM recently. Nearly 63.1% of sites investigate for CM when a patient has symptoms or radiological evidence, while 33.2% investigate only for symptoms. For diagnosis, 71.8% of sites required a positive cerebrospinal fluid cytology, while magnetic resonance imaging findings were sufficient in 23.7% of sites. Roughly 97.1% of sites treat CM and 51.9% also refer patients to palliative care. Intrathecal therapy is used in 41.9% of sites, mainly with methotrexate (74.3%). As many as 20 centers have a national registry for patients with breast cancer with central nervous system metastases and of those 5 have one for CM. Most (90.9%) centers would be interested in participating in a registry as well as in studies for CM, the latter preferably (62.1%) breast cancer subtype specific.CONCLUSIONS: This is the first study to map out the approach to CM from breast cancer globally. Although guidelines with level 1 evidence are lacking, there is a high degree of homogeneity in the approach to CM globally and great interest for conducting studies in this area.
KW - Brain Neoplasms/diagnosis
KW - Breast Neoplasms/pathology
KW - Female
KW - Humans
KW - Medical Oncology
KW - Meningeal Carcinomatosis
KW - Skin Neoplasms
U2 - 10.1016/j.esmoop.2022.100483
DO - 10.1016/j.esmoop.2022.100483
M3 - SCORING: Journal article
C2 - 35576695
VL - 7
JO - ESMO OPEN
JF - ESMO OPEN
SN - 2059-7029
IS - 3
M1 - 100483
ER -
